|
| related topics |
| {product, candidate, development} |
| {stock, price, share} |
| {regulation, change, law} |
| {product, liability, claim} |
| {property, intellectual, protect} |
| {customer, product, revenue} |
| {debt, indebtedness, cash} |
| {provision, law, control} |
| {acquisition, growth, future} |
| {competitive, industry, competition} |
|
|
Most of Our Revenues Have Been Generated by License Fees for TranzFect, Which May Not be a Recurring Source of Revenue for Us
We Have Changed Our Business Strategy, Which Will Require Us, in Certain Cases, to Find and Rely Upon Third Parties for the Development of Our Products and to Provide Us With Products
Our Current Financial Resources May Limit Our Ability to Execute Certain Strategic Initiatives
If Our Products Are Not Successfully Developed and Approved by the FDA, We May Be Forced to Reduce or Terminate Our Operations
The Approach We Are Taking to Discover and Develop Novel Therapeutics Using RNAi is Unproven and May Never Lead to Marketable Products
Our Planned RNAi Subsidiary May Not Be Able to Obtain Sufficient Funding, and We May Not Control a Majority of the Planned Subsidiary if We Obtain Financing
The Drug Candidates Acquired from Biorex May Not Obtain Regulatory Marketing Approvals
Our Obesity and Type 2 Diabetes Laboratory May Not Be Able to Develop Products
We Will Be Reliant Upon SynthRx to Develop and Commercialize Flocor
We Are Subject to Intense Competition That Could Materially Impact Our Operating Results
We Do Not Have the Ability to Manufacture Any of Our Products and Will Need to Rely upon Third Parties for the Manufacture of Our Clinical and Commercial Product Supplies
We May Be Unable to Protect Our Intellectual Property Rights, Which Could Adversely Affect the Value of Our Assets
We May Incur Substantial Costs from Future Clinical Testing or Product Liability Claims
Compliance with Requirements of Section 404 of the Sarbanes-Oxley Act of 2002 Will Increase Our Costs and Require Additional Management Resources, and We May Not Successfully Comply
Our Anti-Takeover Provisions May Make It More Difficult to Change Our Management or May Discourage Others From Acquiring Us and Thereby Adversely Affect Stockholder Value
Our Outstanding Options and Warrants and the Registrations of Our Shares Issued in the Global Genomics Merger and Our Recent Private Financings May Adversely Affect the Trading Price of Our Common Stock
We May Issue Preferred Stock in the Future, and the Terms of the Preferred Stock May Reduce the Value of Our Common Stock
Changes in Stock Option Accounting Rules May Adversely Impact Our Reported Operating Results, Our Stock Price and Our Competitiveness in the Employee Marketplace
Full 10-K form ▸
|
|
| related documents |
| 818033--3/31/2006--AP_PHARMA_INC_/DE/ |
| 849043--3/14/2006--NEUROGEN_CORP |
| 873303--3/16/2010--AVI_BIOPHARMA_INC |
| 819050--2/23/2007--VICAL_INC |
| 819050--3/3/2008--VICAL_INC |
| 318306--5/1/2006--ACCESS_PHARMACEUTICALS_INC |
| 819050--3/3/2009--VICAL_INC |
| 819050--2/25/2010--VICAL_INC |
| 907562--3/4/2009--DYAX_CORP |
| 873303--3/10/2009--AVI_BIOPHARMA_INC |
| 1396238--3/31/2010--IRIS_BIOTECHNOLOGIES_INC |
| 1396238--3/31/2009--IRIS_BIOTECHNOLOGIES_INC |
| 352747--3/16/2007--UNIGENE_LABORATORIES_INC |
| 895051--3/13/2009--ENTREMED_INC |
| 805326--3/17/2008--EMISPHERE_TECHNOLOGIES_INC |
| 882796--3/6/2009--BIOCRYST_PHARMACEUTICALS_INC |
| 908259--3/16/2010--OXIGENE_INC |
| 1123979--2/23/2007--SENOMYX_INC |
| 1123979--2/14/2008--SENOMYX_INC |
| 318154--3/10/2006--AMGEN_INC |
| 908259--3/14/2006--OXIGENE_INC |
| 1012270--3/16/2007--COLLAGENEX_PHARMACEUTICALS_INC |
| 72444--3/10/2010--NABI__BIOPHARMACEUTICALS |
| 1120438--3/15/2006--THIRD_WAVE_TECHNOLOGIES_INC_/WI |
| 1005201--3/16/2006--DEPOMED_INC |
| 1001233--3/16/2006--SANGAMO_BIOSCIENCES_INC |
| 1133416--3/15/2006--PRO_PHARMACEUTICALS_INC |
| 1160308--3/16/2006--ADVENTRX_PHARMACEUTICALS_INC |
| 805326--3/25/2010--EMISPHERE_TECHNOLOGIES_INC |
| 805326--3/16/2009--EMISPHERE_TECHNOLOGIES_INC |
|